Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Carcinoma, Non-Small-Cell Lung 8Esophageal Squamous Cell Carcinoma 7Stomach Neoplasms 4Recurrence 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Lung Neoplasms 3Colorectal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1NSCLC 1Multiple Pulmonary Nodules 1Mid-low Rectal Cancer 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

tislelizumab 1lenvatinib 1Radiomics 1Positron Emission Tomography Computed Tomography 1Pancreaticoduodenectomy 1Electroporation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pancreatic Ductal Adenocarcinoma × tislelizumab × Clear all
NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Fudan University

Phase 1 Completed
56 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡